aceAn analysis of the real world performance of an artificial intelligence based autism diagnostic
Rapidly rising demand for pediatric autism evaluations has outpaced specialist capacity and created a crisis of delayed diagnoses and treatment. Streamlining the diagnostic process could reduce wait times and optimize use of limited specialist resources. Following strong clinical trial results, Canvas Dx, an AI-based diagnostic, was FDA authorized to support accurate diagnosis or rule-out of autism in children 18-72 months with caregiver or healthcare provider concern for developmental delay. To gain insight int…
In real-world use among 254 young children with developmental concern, the AI-based Canvas Dx provided accurate autism predictions with high negative and positive predictive values and enabled diagnosis at a median age of 37.2 months.
Device output was determinate in only 63% of cases, and evaluation was limited to children 18-72 months with caregiver or healthcare provider concern for developmental delay in a small initial sample of 254 prescriptions.
Evidence
- Peer-reviewedScientific Reports2025-08-12
How should this claim be treated?
Truvace Impact Record TRV-2026-0293, v1: “An analysis of the real world performance of an artificial intelligence based autism diagnostic.” Truvace, 2026-07-20. /record/TRV-2026-0293 (accessed at citation time). sha256 df1c312d6c533d21…
Calibration history
Every change to this record since certification, in the open. None yet — the reading has held since it entered the record.
Certified into the record
How to verify without trusting this page
Fetch the canonical text of any version from /api/record/TRV-2026-0293 and hash it yourself — for example shasum -a 256 on the saved canonical field. The result must equal content_hash, and each version’s text ends with prev:followed by the prior version’s hash (version 1 chains to 64 zeros). If a single character of any version had been altered since certification, the chain would not reproduce.